OUTSIDE CANADA · AUSTRALIA · PUBLIC HEALTH ACCOUNTABILITY

Australia COVID inquiry call: cancer claims, vaccine injuries and the evidence

Published 18 September 2026 · Source video published 16 September 2026

John Campbell’s mRNA and new cancers video combines two different arguments: Angus Dalgleish’s claim that COVID-19 vaccination is causing aggressive cancers, and Melissa McCann’s demand for scrutiny of Australia’s pandemic decisions and treatment of injured people. The demand for accountability does not depend on accepting every biological or legal assertion in the speeches.

Watch the source, with the evidence distinctions intact

Watch on YouTube · Dalgleish introduction, about 4:26 · McCann statement, about 14:33

A campaign for an inquiry, not an inquiry’s findings

The venue listing for “Australia We Have a Problem!” at The Juniors Kingsford advertises a 10 September Sydney event calling for a COVID Royal Commission, with Dalgleish among the listed speakers. It is evidence of the campaign and event—not evidence that a statutory Royal Commission has been established or has endorsed the presentations.

McCann’s court case: a pending application is not a liability finding

The related Federal Court proceeding is NSD349/2023, Anthony Leith Rose and others v the Secretary of the Department of Health and Aged Care and others. McCann is associated with funding the case; she is not its named lead applicant. The earlier 10 April 2025 reasons of Justice Anna Katzmann struck out a version of the pleading and required leave for another amendment. That procedural ruling did not establish vaccine causation or the respondents’ liability.

Lawyers Weekly reported on 27 July 2026 that Justice Nicholas Owens reserved his decision on a later summary-dismissal application. McCann’s account that a decision was awaited is consistent with that report. We have not verified a later official disposition; an open-file label alone does not prove that every motion remains undecided. Judicial identities and the procedural limits are documented in the companion JudgeWatch foreign-court source trail, which makes no misconduct allegation.

The spending-law question has a real statutory starting point—but not a proven conclusion

McCann points to the expiry of a special vaccine-spending provision. The official National Health Act compilation confirms that section 132G(3) says the relevant Part had no effect after 30 June 2022. However, section 132G(2)(b) also expressly preserves provision under another part of the Act or another law. The sunset date alone therefore does not establish that subsequent expenditure was unlawful. Determining that would require tracing the actual appropriations, agreements and other legal authority; this review does not purport to supply a court ruling on it.

PBAC’s risk-targeted recommendation predates 2026

The official December 2025 PBAC outcome document records a recommendation for Comirnaty on the National Immunisation Program after an earlier May 2025 consideration. It targets specified older, severely immunocompromised and Aboriginal and Torres Strait Islander adult groups. The committee calls it the first COVID-vaccine PBAC recommendation and a necessary step toward transition from the separate National COVID-19 Vaccination Program.

This is a funding and cost-effectiveness recommendation, not the first TGA safety approval or a court finding that the earlier program was unlawful. A recommendation also should not be conflated with an implemented listing. The document’s price and cost-effectiveness qualifications matter; the video’s simplified timeline is not an adequate substitute for that record.

Claim-by-claim: what the medical sources actually establish

1. The heart-tumour report is a preprint—and did not test integration

The likely source for the heart-tumour anecdote is a 9 September 2026 preprint by Hulscher and colleagues. The video does not give its exact citation, so the match should be treated as likely, not certain. It describes a 35-year-old man with cardiac intimal sarcoma and reports vaccine-construct DNA fragments in archived tumour tissue. Those findings deserve methodological scrutiny; finding a sequence in a tissue extract is not, by itself, proof that it caused the tumour.

The paper’s own section 2.8.1 says its method did not assess—and could not determine—whether the sequences were integrated into the human genome. Its tests examined total extracted DNA, not independently confirmed insertion sites in malignant-cell chromosomes.

There is also a timing correction. The paper records first and second doses in April and May 2021, tumour resection on 30 September, and the booster on 9 December. If this is the case Dalgleish describes, the booster came after the heart tumour had already been removed. That does not resolve a hypothesis about earlier doses, but it contradicts a booster-then-initial-heart-tumour sequence. The paper’s proposed growth acceleration is an inference, not a measured pre-vaccination versus post-vaccination experiment. Read the original PDF, especially pages 5–7, 14 and 18.

2. The lymphoma scans are a real case report, not a population result

The September scan dates match Goldman and colleagues’ 2021 report of rapid progression of angioimmunoblastic T-cell lymphoma after a booster. The patient already had biopsy-confirmed lymphoma before the booster. The authors proposed a possible acceleration mechanism but explicitly cautioned that extrapolation even to other patients with that lymphoma was premature.

This should not be dismissed as merely ordinary post-vaccination swollen lymph nodes: the report concerns a patient with known cancer and suspected genuine progression. Equally, one patient’s timing and scans cannot establish how often an effect occurs or prove a population-wide cancer risk. Open paper PDF.

3. The T-cell study found mixed responses, not universal suppression

Benitez Fuentes and colleagues’ study followed 36 patients with solid malignancies. After the third Moderna dose, 24 had increased spike-specific interferon-gamma responses, 11 had decreased responses, and one remained negative. The smaller exhaustion-marker analysis compared four patients from each response pattern.

The authors called the findings preliminary and urged validation. Measuring responses to a coronavirus antigen is not the same as demonstrating loss of tumour-specific immune surveillance or showing that a booster caused cancer relapse. The subgroup concern is a research question; portraying it as a universal collapse of T-cell cancer control goes beyond the experiment. Open paper PDF.

4. DNA detection, reverse transcription, integration and cancer are different claims

Aldén and colleagues’ 2022 experiment used a liver-cancer cell line in a laboratory. It did not demonstrate cancer-causing integration in vaccinated people; the authors said they did not know whether reverse-transcribed DNA had integrated into the cells’ genomes.

A newer 2025 bladder-cancer case report does explicitly claim integration. It should not be hidden behind the claim that nobody has ever reported such a result. However, its authors call for additional validation and acknowledge that a single case cannot establish causation. A reported sequence match is not independently replicated proof that vaccination routinely creates cancer-driving mutations.

The TGA’s October 2024 statement disputes claims about excessive residual DNA and describes regulatory testing. That statement predates these newer reports; it should not be portrayed as a case-specific rebuttal to a September 2026 preprint.

5. “Turbo cancer” is not a defined vaccine-specific diagnosis

Aggressive disease, rapid relapse and multiple primary cancers are serious clinical realities. Grouping them under a dramatic label does not establish a new syndrome or one common cause. Published work on hyperprogression predates COVID-19 vaccination and arose in a different treatment context.

Some early-onset cancer increases also predate the rollout. NCI’s account of US registry research describes increases in 14 cancer types in at least one younger age group during 2010–2019. That does not explain every later trend. It does mean a post-2020 mortality graph, without individual exposure information and appropriate comparisons, cannot identify vaccination as its cause. We did not independently reconstruct the particular graph in the video.

6. Observational signals require scrutiny, not automatic acceptance or dismissal

A 2025 South Korean insurance-data study reported associations between vaccination and several cancer diagnoses within one year. The publisher carries an editor’s notice that concerns are being investigated—not a retraction notice. A 2026 methodological critique discusses index-date differences, confounding, surveillance and multiple comparisons. Such associations cannot by themselves establish that vaccination initiated or accelerated a tumour.

NCI’s patient-information page states that COVID-19 vaccines have not been shown to cause cancer, recurrence or progression. Its older vaccination-schedule text is not used here as a current dosing guide. The appropriate next step for disputed signals is better-controlled follow-up and independent replication, not declaring either a proven cancer epidemic or that every conceivable delayed effect is impossible.

Recognised injuries must not disappear from the discussion

The TGA’s safety reporting recognises myocarditis/pericarditis associated with mRNA vaccines and thrombosis with thrombocytopenia syndrome associated with the adenoviral-vector AstraZeneca vaccine. Serious and fatal vaccine injuries have occurred. These are distinct adverse-event patterns and should not be conflated with the separate cancer allegations.

McCann’s individual injury accounts are testimony in this source, not cases independently medically adjudicated by PBC. Calling for transparent records, proportionate policy and accessible compensation is compatible with careful causation standards. A report after vaccination is a starting point for assessment—not automatically proof of causation, and not automatically something to disregard.

Why Canadian readers may care

The useful comparison is institutional: how governments disclose safety evidence, justify restrictions, hear injured people and evaluate compensation. Australian legal arguments and program changes do not determine Canadian law or prove that a particular Canadian illness was vaccine-caused.

Medical caution: this is a focused evidence review, not a systematic review or personal medical advice. Do not stop cancer treatment, self-medicate with veterinary drugs, or change vaccination decisions solely because of a video or this article. Discuss your own cancer, treatment, prior reactions and current recommendations with your clinical team.

Source package

Research and retrieval note · Claim-by-claim evidence table · Cited source summaries · Video metadata · Timestamped automatic transcript. The transcript is a record of statements being checked, not a statement that they are true; automatic captions contain errors in names and technical terms.

Related PBC coverage: Earlier Dalgleish cancer-claim review · Jimmy Dore / Dalgleish interview review. This article adds the Australian event and newly identified cardiac-preprint context rather than silently treating an older review as evidence of the new video.